Novartis AG (NYSE: NVS; SIX: NOVN) attains ex-US rights to develop and commercialize new gene therapy treatment for Leber’s congenital amaurosis (LCA).
Spark Therapeutics Inc. (NASDAQ:ONCE) have announced that the company has entered into a licensing and supply agreement for investigational voretigene neparvovec, branded in the US as LUXTURNA, indicated for the treatment of patients with confirmed bi-allelic RPE65 mutation-associated retinal dystrophy. The agreement is understood to include a $105 million upfront payment for Spark with an […]Read full story
12 year clinical study of retinal vein occlusion (RVO) in patients with end stage renal disease shows increased risk compared to control population.
A South Korean retrospective longitudinal clinical study of retinal vein occlusion (RVO) in patients with end stage renal disease (ESRD) has shown that a significant association between ESRD and the subsequent incidence of RVO, following adjustment for possible confounding factors. The study accessed a national database of 1,025,340 randomly selected individuals and focused on an […]Read full story
Stem cell researchers characterize RPE maturation processes required in order to maximise potential of transplanted cells.
Collaborative research, led by investigators at the Institute of Molecular Physiology, Johannes-Gutenberg University, Mainz, Germany, and the US National Eye Institute, NIH, Bethesda, Maryland, have shown that the success of transplantation of stem cell derived RPE to the retina is critically dependent on correctly functioning RPE cilia. The study is published in Cell Reports 22, […]Read full story